Latest / EU-Startups Podcast / How European BioTech is Changing Cancer Care

Transcript

How European BioTech is Changing Cancer Care · EU-Startups Podcast

• 0:00
  Speaker 2: You are now listening to the EU Startups Podcast.
• 0:13
  Speaker 0: Hello, and welcome to a special episode of The EU Startup's podcast!
• 0:16
  Speaker 0: As always I'm your host and editor, Deniz Sanongarcia.
• 0:19
  Speaker 0: Today I chat with Inna Muriel and Emily—the three are founders of different cancer care companies across.
• 0:28
  Speaker 0: Each of them focus on a different angle of cancer care.
• 0:31
  Speaker 0: And we were able to chat over what their companies offer, how they're innovating even the current development of companies within Europe especially Mentec and HealthTech companies... ...and what it's like to scale from research institution into startup.
• 0:47
  Speaker 0: They are also all former awardees for Women Tech EU program.
• 0:52
  Speaker 0: Now for those of you that don't know, WimTechEU is an EU-funded funding scheme which supports women led deep tech startups across Europe.
• 0:59
  Speaker 0: Selected applicants receive a combination investor connections, network opportunities and support in tapping into further EU funding.
• 1:19
  Speaker 0: By opening doors for diversity in deep tech women TechEU is one of the most impactful tools helping shape a more competitive European ecosystem.
• 1:27
  Speaker 0: so I hope you're looking forward to this episode.
• 1:31
  Speaker 0: Hello, all and welcome to this special episode of the You Starts podcast.
• 1:35
  Speaker 0: Thank you for joining me Ina Muriel and Emily.
• 1:38
  Speaker 0: It's a pleasure have three view on...you might not know This but there is actually first round table Episode that i've done under my tenure Of The Podcast so looking forward To be able to chat with All of you And kind of had Discussion more varied than I usually get With this topic.
• 1:55
  Speaker 0: So thank you all For coming to join.
• 1:57
  Speaker 0: Thank you.
• 1:59
  Speaker 0: Yes, yes But I won't let y'all guys to speak over each other because that will lead to a lot of hassle.
• 2:03
  Speaker 0: but I am thankful for you joining me.
• 2:07
  Speaker 0: As our viewers probably know already from just the way this episode structured This episode is coming to fruition through our partnership with women tech EU.
• 2:17
  Speaker 0: Each of you and your companies are former awardees of the program And i think it's kind of anchor for our conversation today to be able to chat over each of your advancements, what you're doing in terms of cancer care and how that program has helped you out.
• 2:33
  Speaker 0: But before we get into it I want give you a chance to present yourselves.
• 2:37
  Speaker 0: Inna why don't we start?
• 2:40
  Speaker 2: Hi hello David so my name is Inna Minkova and i'm a scientific co-founder and CEO of Allogenica.
• 2:48
  Speaker 2: It's based by a company where developing universal cell therapy for pediatric cancers.
• 2:55
  Speaker 0: Great, Muriel why don't you go now?
• 2:58
  Speaker 3: Hello David, hello everyone.
• 3:00
  Speaker 3: I'm Muriel Bardot.
• 3:01
  Speaker 3: I am the CEO and co-founder of Alga Biogix which is a French deep tech company that we created almost five years ago now... ...and it's using macroalgae as a cell biofactory to produce therapeutics antibodies And our first pharmaceutical candidate is targeting a pediatric cancer.
• 3:21
  Speaker 0: Great thank you Emily.
• 3:24
  Speaker 1: So my name is Emily Fong, I'm the founder & CEO of InxFocus Therapeutics Infocus is an AI-native biotech company, and we're building a cutting edge computational platform that can design small molecule drugs to target RNA targets.
• 3:39
  Speaker 1: So the benefit is that we can drug diseases that's previously been really difficult to touch.
• 3:47
  Speaker 0: Okay, so I mean at least and i'm quite the layman on all of this.
• 3:51
  Speaker 0: So I understand very little but at least from what you've each told me there is quite a different approach.
• 3:57
  Speaker 0: Each of view has to be idea of cancer care And whenever I talk to medtech or health tech founders There usually Is A Personal Connection Or At Least The Reason Why They Got Into This Field To Begin With?
• 4:11
  Speaker 0: with you three and hear about there's kind of a personal connection to all this, or at least what got you interested in the field.
• 4:18
  Speaker 0: Inna why don't we start?
• 4:21
  Speaker 2: Thank You very much!
• 4:23
  Speaker 2: So my personal connections is actually coming from my scientific life which has always revolved around T cell development.
• 4:31
  Speaker 2: so during my PhD work I worked on what they call precursor T cells And I became really fascinated by the way that nature creates actually safe and functional cells later.
• 4:45
  Speaker 2: So working in cell therapy, I saw both its extraordinary potential So we have this powerful technologies, but they were too complex to expensive.
• 4:57
  Speaker 2: Too largely unable to address cellulet cancers.
• 5:01
  Speaker 2: so I founded Allogenica because i believed that we could go back into the biology engineer T-cells before their fully exist and build a new generation of therapies which can actually reach pharma patients particularly children and young adults.
• 5:19
  Speaker 0: thank you Inna Muriel.
• 5:20
  Speaker 3: Yes, so for me.
• 5:21
  Speaker 3: of course I have some relatives who suffered and sometimes died from cancer.
• 5:30
  Speaker 3: And while we are improving in the development of new therapeutics like antibodies there is a paradox as we're producing these antibodies by using mammalian cells which is so costly that only five percent worldwide population can afford to have these therapies therapies.
• 5:49
  Speaker 3: So when I was working in academia like ENA, iI was starting to take on this problem and started to develop a macroalgae as the new way to produce cheaper ways with more sustainable ways of producing such kind of therapies.
• 6:07
  Speaker 0: Thank you Emily.
• 6:09
  Speaker 1: Um.
• 6:10
  Speaker 1: so myself have spent all my career over fifteen years in drug discovery and drug development.
• 6:16
  Speaker 1: really coming together.
• 6:17
  Speaker 1: is what's my co-founding team for infocus My technical co-founders, they've spent also all of this time in the first wave with these AI biotech companies.
• 6:27
  Speaker 1: So we really got together to think what are still... What would call the undruckable space?
• 6:32
  Speaker 1: A lot of difficult diseases that still lack effective treatments like metastatic cancers across different indications.
• 6:40
  Speaker 1: so I think our mission is very much
• 6:43
  Speaker 0: committed
• 6:44
  Speaker 1: to really serving patients, to see what we can actually create meaningful medicines that could actually make an impact with patient.
• 6:52
  Speaker 1: So cancer is still of course just a lot R&D research activities but it's the high on medical needs especially in second line and late-night treatments.
• 7:01
  Speaker 1: so that's where were committed too.
• 7:02
  Speaker 1: tackle.
• 7:04
  Speaker 0: okay Each of you, obviously has a big problem to solve and your addressing it.
• 7:11
  Speaker 0: And there's so much theory in everything that you're kind of talking too and developing which makes me be curious about the practical element over all how the process is getting into patients.
• 7:24
  Speaker 0: actually I'm curious at least from what experience each one have.
• 7:27
  Speaker 0: From my understanding they are based on France correct?
• 7:30
  Speaker 0: Me if i am wrong but this is full French kind of a panel here, at least for the companies.
• 7:36
  Speaker 0: Right?
• 7:36
  Speaker 0: So I think you can all speak from the same home turf then and The question is about just how Well How difficult has it been in the process Of taking out-of-the-lab And take it out of research and theory into hospitals and into practice What that whole process has been free to do You know why don't we continue this rhythm first?
• 8:02
  Speaker 2: Actually I think it's quite difficult, especially in Europe because i really feel that we have a gap between great science and actually translational medicine.
• 8:19
  Speaker 2: Breakthrough they never fail in the lab.
• 8:21
  Speaker 2: They always failing translation, what doesn't mean it then you have a great product and do still need to manufacture them than bring to the patient go through the regulatory path and also produce it reliably at scale to be delivered as to as many patients possible.
• 8:37
  Speaker 2: so here there is a huge a huge gap where we actually cannot get into the good capital aligning with processes, timeline and translational steps of new medicines.
• 8:55
  Speaker 2: So for me this was most difficult part to go and reach lots of patients.
• 9:04
  Speaker 0: Thank you Ina.
• 9:04
  Speaker 0: Muriel?
• 9:05
  Speaker 3: Yes, so for us when we started... We created the company.
• 9:08
  Speaker 3: In fact, we were at lab scale in terms of capacity of production.
• 9:12
  Speaker 3: So one of our first challenges that needed to tackle was to scale up a technology.
• 9:19
  Speaker 3: So we already demonstrated our capacity to scale-up and we are now able To do some batches with two hundred litres which means That's where I'm able to produce several hundreds of milligrams of protein but still need to improve the production yield and also continue to scale up before being able to produce enough in order reach for patients.
• 9:42
  Speaker 3: We know that we will take some more times, pass these steps into improving technology without making it enough to reach a clinical stage.
• 9:55
  Speaker 0: Thank you Emily.
• 9:58
  Speaker 1: On our side because focusing with all had some experience, decades of experience in drug development.
• 10:04
  Speaker 1: So... In a sense we actually work from the needs back up to discovery and technology.
• 10:11
  Speaker 1: so I think there's thinking that it has to be sequentially come out with innovative technologies you discover molecules medicine then look at where It can it couldn't be applied the applications and patients.
• 10:24
  Speaker 1: But we really start from the patient need, and we define what would call the target product profiles.
• 10:29
  Speaker 1: I think everybody's quite aware meaning that What is?
• 10:34
  Speaker 1: The disease needs And is there still a therapy That can improve on the current standard of care.
• 10:41
  Speaker 1: Then We go backwards to see if for example in our case targeting RNA If targeting RNA with small molecules or some modality actually has an impact so kind of this.
• 10:51
  Speaker 1: I think there's obviously a gap between what we call the bench and bed sign, right?
• 10:55
  Speaker 1: So it could be the lab in patient.
• 10:59
  Speaker 1: In our example even at this stage where only two years old as well is start-up but already talk to clinicians or close to patients groups We tried to define therapeutics that were trying design before get into AI technologies.
• 11:15
  Speaker 1: And don't try expend endless resources on bad end if the outcome is not actually making an impact in a clinic.
• 11:24
  Speaker 0: Okay, okay.
• 11:25
  Speaker 0: so I mean it seems that each of you are definitely in the process of scaling what your product and your technology and offering and obviously come across some challenges but have a thesis on how to address them?
• 11:39
  Speaker 0: That brings me naturally into another question which i know uveach raised funding as well its own accomplishment kind of what goes beyond funding, especially as we mentioned in the beginning.
• 11:52
  Speaker 0: You're all former, over days at the Women Tech EU program and I think it's a good moment to acknowledge other helps that your companies have received.
• 12:14
  Speaker 2: So basically, this grant was very valuable because the most important change was certainly the credibility.
• 12:22
  Speaker 2: Because we have like a label of European Commission and Women Tech U And it became really a label.
• 12:31
  Speaker 2: so at early
• 12:32
  Speaker 1: stage
• 12:34
  Speaker 2: The external validation means really a lot and that matters a lot having this woman that you European label signals, the science company and founder were worth backing.
• 12:49
  Speaker 2: So beyond visibility I would also say access to women building ambitious projects was really important.
• 13:00
  Speaker 2: And here we are like happened work around same subjects but met a lot of women working outside of the biotech, outside other domains.
• 13:12
  Speaker 2: we would never met elsewhere.
• 13:15
  Speaker 2: So this was quite important because I understood that the internship can be isolated particularly when we are building a capital-extensive bioteche company but actually all having the same problems and sharing them to see how it could be creative.
• 13:34
  Speaker 2: it's quite a rich exchanging between different overgives.
• 13:44
  Speaker 3: Yeah, like I mentioned it was a rich moment to exchange all together and see that we were facing the same challenges.
• 13:53
  Speaker 3: To share also some advices together.
• 13:56
  Speaker 3: but in addition to this visibility of course gives credit for projects which help us open doors with investors who are facilitators.
• 14:10
  Speaker 3: And I will say that for us, at least in Al-Ghaba, it helps also to challenge a lot our business model through the discussion we got with the mentor and also from different training workshops organized by women TechU community.
• 14:25
  Speaker 3: This was exactly what we needed at this time which is really useful so as to find the right path.
• 14:34
  Speaker 0: Thank you.
• 14:35
  Speaker 0: Emily?
• 14:39
  Speaker 1: It's all of those things, I think maybe something.
• 14:44
  Speaker 1: A lot of the mentoring sessions themselves for in our case we've been supported and friends but on a European level that this was our first program.
• 14:54
  Speaker 1: so even learning how to access it is interesting as what are different entities like EIC etc.
• 15:04
  Speaker 1: from their basic levels to understand what are the expectations and what we can have access.
• 15:10
  Speaker 1: I think for a startup, or first time founder that's oftentimes like the learning curve right?
• 15:16
  Speaker 1: To know kind of opportunities actually fit where with-where were you're kinda profiles in company.
• 15:21
  Speaker 1: so uh...I was really helpful.
• 15:23
  Speaker 1: So it got really concrete benefits from it
• 15:26
  Speaker 0: Right!
• 15:28
  Speaker 0: The reason why i ask is because there's so much dialogue goes around funding.
• 15:32
  Speaker 0: We're also guilty of that in terms our coverage.
• 15:36
  Speaker 0: The eighty, ninety percent is about who's raising money and how much they are raising.
• 15:40
  Speaker 0: but there always kind more argument to say a lot.
• 15:44
  Speaker 0: startups new companies can benefit from these programs isn't just here as money you know sometimes the only answer it not problem.
• 15:53
  Speaker 0: Sometimes it's connection, sometimes its community.
• 15:55
  Speaker 0: And these things play a role into the success of how something develops.
• 15:59
  Speaker 0: So off-the-back talking about community and all this together I'm not going to go individual.
• 16:04
  Speaker 0: I am gonna kind focus on each one in quick seconds.
• 16:07
  Speaker 0: It is also important that you give each of your way A quick highlight and spotlight To get deeper towards what they do.
• 16:15
  Speaker 0: Let us begin with now.
• 16:17
  Speaker 0: As i mentioned before Im a layman so you will excuse my ignorance In any topic But when we're looking over what your company does, I did have the feeling that the offering at least right now is complex and it's very individualized in things you can do.
• 16:35
  Speaker 0: And I'm wondering if this may be a result of bottleneck for wider adoption with different countries or large groups of population who might want to apply technology too?
• 16:50
  Speaker 0: What are they looking like?
• 16:53
  Speaker 2: Yes, you are exactly right David.
• 16:54
  Speaker 2: Actually today the cell therapy is a one hundred percent personalized product so it's complex that costly and all patients who needed cannot actually have access to it.
• 17:05
  Speaker 2: So in order to become universal we need to create truly off-the-shelf products being available Right now at reduced cost.
• 17:16
  Speaker 2: For me personally, to have this product come-to-life we need to change like three things.
• 17:21
  Speaker 2: We need the starting material with needs of changing manufacturing and we needed a change in biology for products.
• 17:29
  Speaker 2: so basically today what you do is that we take cells from patients then modify them in order they are able recognize and kill cancer cells and re-inject back to their patient.
• 17:40
  Speaker 2: So thats where complexity comes.
• 17:45
  Speaker 2: So, what we need to do is that... We need to produce a treatment from a particular donor and then handle with the rejection which arrives completely naturally when it would take some cells of one person and inject them into someone else.
• 18:05
  Speaker 2: Second for me, manufacturing definitely must be designed from day zero with reproducible process where clearly defined quality attributes.
• 18:20
  Speaker 2: but the manufacturing loan is not sufficient.
• 18:23
  Speaker 2: The sales must also remain functional, persistent and safe after treatment.
• 18:28
  Speaker 2: so that's what we are doing exactly at Allogenica because we address these three dimensions by engineering cells which are precursors before they become fully natural and we produce them in batches.
• 18:41
  Speaker 2: We allow the nature to complete their maturation, this means that off-the-shelf products are available just as simply frozen bag after all which is a completely standardized product which remains biologically fit for purpose.
• 19:02
  Speaker 2: so it's how you handle these complex cell therapy problems.
• 19:08
  Speaker 0: Is then their wider issue as well, because we're talking about European scaling and applying to all these.
• 19:13
  Speaker 0: But if you were thinking of going through the US or Asia abroad how deep a change would have to go though your processes in order get them approved abroad?
• 19:27
  Speaker 0: I
• 19:31
  Speaker 2: would not say about the China, because in China they have a particular regulation which actually doesn't allow sales to travel across the borders.
• 19:40
  Speaker 2: So basically everything you manufacture on Europe cannot be imported into China and everything manufactured in China can be exported.
• 19:49
  Speaker 2: However with US there are good parallels the both regulatory agency, that European medicine agencies EMA and FDA are quite compliant.
• 20:01
  Speaker 2: And then requestments of their requests.
• 20:03
  Speaker 2: so this is quiet.
• 20:06
  Speaker 2: I would not say easy but it's definitely possible to expand a European product into US and this versa.
• 20:13
  Speaker 0: Okay Thank you Inna.
• 20:14
  Speaker 0: move on to Muriel now when i was looking over You know everything what she doing?
• 20:20
  Speaker 0: It's its I'll say I didn't quite.
• 20:23
  Speaker 0: It surprised me to be reading about microalgae producing antibodies, and that's on something one I understand.
• 20:30
  Speaker 0: And two makes me curious how you even arrived at the point because it doesn't seem like a standard way of arriving cancer care through microalgy.
• 20:40
  Speaker 0: so could you talk us though little bit?
• 20:43
  Speaker 3: Yeah in fact what we need is right now antibodies are used for treating cancers during the immunotherapy treatment.
• 20:54
  Speaker 3: And the antibodies that are injected to human are currently produced by using mammalian cells, which is very costly polluting involves a very complex process and it's always at risk of viral contamination because the virus can infect the mammalian cell also infects patients.
• 21:13
  Speaker 3: so this means that supplier needs some additional steps to make sure that they remove all the potential virus from the antibody which are prepared as a bio-drugs.
• 21:26
  Speaker 2: So
• 21:26
  Speaker 3: starting with this problem, in fact we were thinking... Which kind of organism can replace mammalian cells and be able to produce such complex molecules as antibodies without causing the same kinds of trouble?
• 21:42
  Speaker 3: And it was obvious that photosynthetic organisms could be the right solution!
• 21:47
  Speaker 3: So that's from where we tackle the problem and started to investigate the use of macroalgae for such kind of production.
• 21:57
  Speaker 3: Of course, naturally microalgae are not able to synthesize antibodies so know-how is how we can program them in order to make them produce antibodies on demand.
• 22:12
  Speaker 3: So we did several production of antibodies.
• 22:15
  Speaker 3: Some of the antibody that were produced will be very soon available for research and diagnostic application, And now like INA we need to go through a regulatory approval in order make validation on this innovative production system To make sure you can produce some clinical batches or commercial batches of antibodies used as biologics.
• 22:42
  Speaker 0: And did this begin originally in a research institution or is it fully with the idea of company?
• 22:48
  Speaker 3: No, no.
• 22:49
  Speaker 3: In fact I was the scientist working on development technology during more than fifteen years at the University of Rwanda Monday.
• 22:58
  Speaker 3: And then at one point, when we came out with different proof of concept and... We had this problem of scaling up the technology to demonstrate that it will be useful at an unusual scale.
• 23:09
  Speaker 3: It's so when we decided to create Alga biologics.
• 23:12
  Speaker 3: So almost fifteen years I'm working on the development of a technology.
• 23:18
  Speaker 3: We are real deep tech company!
• 23:20
  Speaker 3: That's
• 23:22
  Speaker 0: true.
• 23:23
  Speaker 0: We'll move on to Emily here.
• 23:25
  Speaker 0: now, from what I understand and what you do is that your mixing AI generative chemistry in new design drugs right?
• 23:33
  Speaker 0: And specifically it's drugs are targeting RNA.
• 23:35
  Speaker 0: Now I kind of was curious if he could walk me through a little bit as too.
• 23:39
  Speaker 0: What makes that different form traditional drug discovery?
• 23:43
  Speaker 1: So think we probably hear about all the application for AI life sciences mixed in use quite a lot In drug discovery, perhaps on a high level.
• 23:54
  Speaker 1: you can think of it as at least for small molecule drug discovery.
• 23:57
  Speaker 1: You can think either from the biology angle.
• 23:59
  Speaker 1: so there's companies and groups trying to tackle to see if AI could be applying to look out what biological targets are still rather relevant disease or relative to their own unexplored that we cannot go after them.
• 24:13
  Speaker 1: And then in this small molecule case is down the chemistry side If I use these computational technologies to design or generate a lot of molecules, right?
• 24:22
  Speaker 1: That we can test.
• 24:24
  Speaker 1: And at some points it's not that.
• 24:26
  Speaker 1: the field has been around for probably over decade and what would call chemical space is like spent into all the possible molecules.
• 24:33
  Speaker 1: I could though we can possibly tap in too.
• 24:37
  Speaker 1: so before you need this human medicinal chemist who understand chemistry to do the design but now he can rely on computers Angle is that we're really looking at the RNA targets specifically.
• 24:53
  Speaker 1: so were more specialized or focused.
• 24:56
  Speaker 1: The algorithms and modules of technologies are building our really for this particular target space.
• 25:03
  Speaker 1: Why RNA?
• 25:03
  Speaker 1: So if you remember a little bit like high-scoot biology, we have DNA that get transcribed into RNA and they can translate it to proteins.
• 25:11
  Speaker 1: so a lot of parts are not aware... A lot more traditional conventional drug discovery over the last six to seventy years has been focused on protein called the workhorse in the cells when it goes awry or disease arise.
• 25:23
  Speaker 1: but now there's lots of proteins which you can't really go after because they're structures, you know.
• 25:29
  Speaker 1: They may be what we kind of call colloquially like slippery on the outside that can't really find something to it.
• 25:36
  Speaker 1: so The ideas are you could go upstream right?
• 25:38
  Speaker 1: So RNA if It's a part of instruction That you give two to produce proteins actually can tackle that way.
• 25:45
  Speaker 1: We hear about RNA Medicines here about a gene therapy CRISPR medicines.
• 25:50
  Speaker 1: the concept is this thing.
• 25:51
  Speaker 1: so in the AI direct discovery space that still relatively new to be able to lean onto these waves of AI models or methodologies, see if it can help.
• 26:04
  Speaker 1: Not only accelerate the process but I think we talk about that a lot.
• 26:08
  Speaker 1: how is AI helping to speed things up?
• 26:10
  Speaker 1: But in our group like really focus on how he's helping us make decisions right...to decide which molecules advance into next phase experiments Which ones have higher confidence and success.
• 26:23
  Speaker 1: really like the ethos of building companies.
• 26:26
  Speaker 1: It's not just speed, but quality decisions and that's what I emphasize quite a lot.
• 26:32
  Speaker 0: Okay so from my understanding obviously you're intertwined with AI development kind of advancement in these models and how everything is shaping up.
• 26:42
  Speaker 0: So does this mean as AI grows will our drug discovery?
• 26:49
  Speaker 0: Is it so exponentially connected to that?
• 26:52
  Speaker 0: or is there another factor?
• 26:54
  Speaker 1: That's the top question.
• 27:00
  Speaker 1: I think what we instinctively know, obviously biology is complex disease.
• 27:04
  Speaker 1: biologists are talking about a lot of dimensions whether molecular, biochemical biophysics level to the cell.
• 27:13
  Speaker 1: To the organs of the physiological systems too even like person-to-person right?
• 27:20
  Speaker 1: Like what we're talking about a clinical setting.
• 27:23
  Speaker 1: so there's a lot to unravel and it's at some point would call its system biology right since systems concept everything place into each other, there's redundancies built in two biological systems.
• 27:37
  Speaker 1: There is a lot to understand.
• 27:40
  Speaker 1: even so I think that it definitely has the level of humility we need have right?
• 27:45
  Speaker 1: So if you can only understand small percentage biology how do we expect algorithmic system to kind of tap into problem?
• 27:55
  Speaker 1: but come back whether or not it could be useful tool for health as well and just our day-to-day way to conduct our discovery and development.
• 28:06
  Speaker 1: If for a single team, you know if are chemists or biologists perhaps in the past they can handle a handful of projects in a year right?
• 28:14
  Speaker 1: So with these tools that really explore more hypothesis than do more so we kind think it's one of them powerful takeaways that we don't talk as much about.
• 28:25
  Speaker 1: It revolutionizes the space, et cetera.
• 28:27
  Speaker 1: but perhaps it can lead us to testing more ideas and maybe that can broaden this space.
• 28:35
  Speaker 1: But I come back to... The same thing you were talking of funding does tie into it.
• 28:41
  Speaker 1: In our particular tech biospace You have investors who work on the tech or the bio.
• 28:47
  Speaker 1: All that is connected in an ecosystem.
• 28:50
  Speaker 1: And yeah, we're doing our best and I think making some progress.
• 28:55
  Speaker 0: Okay, well thank you to all three of you.
• 28:58
  Speaker 0: That's I think a nice little Spotlight on each of you.
• 29:01
  Speaker 0: obviously we could continue on and i'm sure there are many more questions that can ask.
• 29:05
  Speaker 0: but for sake of brevity And then kind get people interested in what they do is very good introduction.
• 29:11
  Speaker 0: With this in mind my final question here.
• 29:14
  Speaker 0: just wrap things up.
• 29:16
  Speaker 0: This follow-up question is aimed at the scientists among our viewers, and I generally don't really address them that much.
• 29:28
  Speaker 0: So it's a good opportunity to do
• 29:30
  Speaker 0: so.".
• 29:31
  Speaker 0: And just ask if you had any tips or suggestions that you would give to scientists who are people involved in health tech?
• 29:40
  Speaker 0: Whatever is when they have ideas and looking at bringing this into market.
• 29:43
  Speaker 0: what kind of something maybe you wish was known from the beginning?
• 29:55
  Speaker 2: It's always complicated to give it boxes for the people, you know.
• 30:00
  Speaker 2: But let's say I'll give a feedback that would love actually hear in the beginning.
• 30:09
  Speaker 2: Or we'd love somebody actually tell me that company is not simply vehicle around great science but also need momentum build product which is designed correctly, and by a product I mean that we build the right team with the right financial strategy intellectual property manufacturing in clinical position.
• 30:33
  Speaker 2: So all this actually the company not only the science can still evolve.
• 30:43
  Speaker 2: so you have ambition to communicate with different scientists, clinician regulator and investors.
• 30:53
  Speaker 2: And this will make your science evolve.
• 30:56
  Speaker 2: so a piece of advice would definitely be don't fall in love with the first solution but falling in love That's
• 31:04
  Speaker 0: a good tag line.
• 31:06
  Speaker 0: Muriel?
• 31:07
  Speaker 3: Yeah, for me my advice would be to especially some biotech or deep tech company To mature the technology The more you can in your lab before creating the company so that You reach momentum where are ready to be financed by the investor and it will make Your life much easier as beginning of the company.
• 31:32
  Speaker 3: So in addition to what Ines says, that will be my advice too.
• 31:36
  Speaker 3: To mature the technology as much as you can in your lab before creating the company so that at right moment of creation of a company.
• 31:45
  Speaker 0: Got it Emily?
• 31:48
  Speaker 1: On my side I think its concept is risk if we are talking about scientists who want to become scientist entrepreneur or founder.
• 31:58
  Speaker 1: I think on some level, it's a mild contradiction because in science where we're learned that there is at some level of being conservative and being rational.
• 32:07
  Speaker 1: And things thoughtful thinking through what i've come to appreciate as the entrepreneurial impulse.
• 32:15
  Speaker 1: you do have just to try something out meaning It can kind of have this concept, whether the science or technology may not work out there in the market.
• 32:34
  Speaker 1: So whatever that refers to but I think you do just have to attempt it.
• 32:40
  Speaker 1: and That being said...I Think The translation from Technology To something that's close too In our world is not directly selling to somebody to the consumer.
• 32:53
  Speaker 1: so we understand that space We're actually selling two Because you need to understand that question, and be able to speak about trying to get investors to fund what they're doing.
• 33:02
  Speaker 1: So I find it may seem kind of logical but a lot of the scientists think this would be a problem for them.
• 33:14
  Speaker 1: You do have to broaden the space, which is really out of your comfort zone.
• 33:19
  Speaker 1: We're used to thinking about small but very special and a small problem or very specialized problems can go with protocol.
• 33:26
  Speaker 1: experiments were going design analyze data by starting a company.
• 33:30
  Speaker 1: so much part in that.
• 33:31
  Speaker 1: like you guys said it's definitely challenge.
• 33:34
  Speaker 1: I would encourage talking too as much as you can reach out whether its other founders entrepreneurs ecosystem mentors advisors try not Think you try to think your way really hard.
• 33:48
  Speaker 1: it's a problem that is a lot of the time.
• 33:50
  Speaker 1: You can't have to go into network.
• 33:53
  Speaker 1: so that would be my advice,
• 33:56
  Speaker 0: right?
• 33:56
  Speaker 0: Well I know the purpose of these episodes is always to being informative one as well as kind of interest pieces and i think there was alot value in what we chatted about today So much on learning all three but also understanding process journey through this ecosystem.
• 34:12
  Speaker 0: You know, I think your success is our success really and if all three of you do very well then we're all excited to get a benefit from that.
• 34:20
  Speaker 0: So on that note i want to thank all three for joining me.
• 34:23
  Speaker 0: it's been an absolute pleasure!
• 34:25
  Speaker 0: And uh...I hope to hear from all of you again soon.
• 34:27
  Speaker 0: Thankyou
• 34:29
  Speaker 3: very much Amit!
• 34:31
  Speaker 0: Thank you!
• 34:31
  Speaker 0: Applications for the Women TechEU program are currently open.
• 34:37
  Speaker 0: The eligibility strand remains open until the thirteenth July.
• 34:40
  Speaker 0: twenty-twenty seven with weekly cutoff dates.
• 34:42
  Speaker 0: Eligible applicants can then proceed to apply for one of the four full-submission deadlines that will be issued over next year, the closest being on September the sixteenth.
• 34:52
  Speaker 0: If you're a woman founder leading an early stage deep tech startup in eligible country visit The Woman Tech U website and learn more about this program.
• 34:59
  Speaker 0: Check your eligibility and Apply!